Active substance
Results for the substance asciminib
3 results
About this active substance
Asciminib is a medication used in the treatment of chronic myeloid leukemia (CML) in patients who exhibit resistance or intolerance to other therapies. It is a BCR-ABL1 protein inhibitor that works by blocking the activity of this abnormal protein, which is responsible for the uncontrolled proliferation of leukemic cells.
Asciminib is administered orally in tablet form and is often used in cases of CML with specific mutations or when other treatments are ineffective. It is considered a targeted therapy with a more favorable safety profile compared to other options.
Common side effects include nausea, fatigue, headache, and elevated liver enzymes. In rare cases, severe adverse reactions such as thrombocytopenia or allergic responses may occur. Regular monitoring is essential for dose adjustment and complication prevention.
Asciminib represents an innovation in the treatment of chronic myeloid leukemia, offering an effective and well-tolerated option for patients with this condition.
Asciminib is administered orally in tablet form and is often used in cases of CML with specific mutations or when other treatments are ineffective. It is considered a targeted therapy with a more favorable safety profile compared to other options.
Common side effects include nausea, fatigue, headache, and elevated liver enzymes. In rare cases, severe adverse reactions such as thrombocytopenia or allergic responses may occur. Regular monitoring is essential for dose adjustment and complication prevention.
Asciminib represents an innovation in the treatment of chronic myeloid leukemia, offering an effective and well-tolerated option for patients with this condition.
-
-
SCEMBLIX 20mg film-coated tablets EUROPHARM ORIGINAL MEDICINE
-
SCEMBLIX 100mg film-coated tablets EUROPHARM ORIGINAL MEDICINE